The possibility of gene editing to correct disorders is one of the most impactful therapeutic 10 agents, currently. CRISPR Cas9-sgRNA nucleases can be used to cleave and to delete harmful or 11 pathogenic DNA sequences, which cause genetic disorders. Cas9 nuclease includes palindromic 12 repeats that cut and delete a single point mutation or multiple DNA target site sequences. The
Introduction
Survey Methodology 75 Research Questions: What are the current challenges of the Cas-9 nuclease? How can the 76 delivery of Cas9-sgRNA be improved? Can lipid-nanoparticles improve delivery of Cas9? Can 77 oral ingestion of lipid-based nanoparticles with Cas9 become a more effective approach for its 78 delivery? Why may the GI tract be a more successful route for Cas9 delivery? The four articles were eliminated based on their title and abstract, which did not align with the 87 search terms. The first article was eliminated because it reviewed the coagulation or blood 88 clotting gene mutations corrected by CRISPR gene editing, the 2 nd article's title included the 89 term Rheumatoid Arthritis, the 3 rd article studied muscular dystrophy, the 4 th article only 90 discussed the history or the development of CRISPR nucleases.
91

Issues and Methods for CRISPR CAS9 Delivery
92
Some challenges for targeting genes include sgRNA design. For example, challenges 93 with Cas9 occur when sgRNA-2 and sgRNA-5 detect and change the wildtype and the mutant 94 genes for the mCrygc embryonic stem cells or ESCs. The sgRNA-1, sgRNA-3, and sgRNA-4 95 only target the gene mutation of mCrygc. The sgRNA-4 was selected due to it inducing 96 deletions, insertions, and it closely targets the mutant allele. To correct the mutation that causes 97 cataracts, a mouse model was used. Zygotes were injected with Cas9 mRNA and sgRNA-4 and 98 were the offspring of females that procreated with homozygous males, expressing the phenotypic 99 cataracts. Approximately 91 percent of the zygotes matured into embryos and 22 mice were born 100 (Wu et al., 2013) . Of all the 22 mice none of the wildtype alleles were affected or changed, 101 showing the accuracy of sgRNA-4 to only target the mutant alleles.
102
Other challenges may occur with direct injection or through unguided Cas9. The Cas9 103 mRNA, sgRNA-4, and Oligo-1 were injected into the cytoplasm to test rather adding a single-104 stranded DNA oligo called Oligo-1 can make HDR-mediated precise genome more efficient. The 105 coinjection was projected into the cytoplasm of heterozygous cataract mutation-bearing zygotes.
106
The results included: the DNA sequencing 14 of the 29 mice displayed gene changes in the 107 mutant allele (Wu et al., 2013) . Nine of the fourteen mice did not form cataracts. To genetically 108 edit the Fah gene three sgRNAs: FAH1, FAH2, and FAH3, were cloned into the plasmid pX330.
109
The vector pX330 expresses sgRNA and Cas9 complementary to the target gene mutation. Mice 110 were then injected with unguided Cas9 or with ssDNA oligos with pX330, dispatching Cas9 and one of the sgRNAs of FAH1 to FAH3. The unguided Cas9 injected mice needed to be 112 euthanized due to their 20 percent loss of body weight (Yin et al., 2014) . The FAH-2 injected 113 mice after 30 days exhibited less liver damage and disease. After the histological analysis of the 114 liver of the mice, applying serum biomarkers as aspartate aminotransferase, AST, alanine 115 aminotransferase (ALT), and bilirubin to the liver, the Fah gene increased with less liver 116 damage. Next, the structure and function of the immune system and the Peyer's patches within 117 the gut will be discussed. The general mechanism involves a drug compacted within a liquid and solid lipid. The 139 drug travels through the small intestines, and then binds to M cells that line the lumen of the 140 intestines. The drug transports through the M cells to be engulfed and phagocytized by NCLs 141 (Fig.1) . The drug is carried by dendritic cells to the Peyer's patch and released into the lymph 142 nodes for lymphatic circulation. In the lymph nodes the dendritic cells release the drugs to enter 143 blood circulation. Therefore, the route of drug ingestion and delivery through the intestines may 144 be a high-yielding method for a direct interaction between the immune cells, the circulatory 145 system, and Cas-9-sgRNA nucleases. However, Cas9 nucleases will require packaging into lipid-146 based nanoparticles to successfully cross the lipid bilayer of the M cells. 
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Bacteroidetes and Firmicutes are the only bacteria in the gut microbiome that use 216 enzymes called cellulosomes that bind to the cellulose of plant cell walls. Activating the 217 cellulosome, bound to cellulose, the glyosidic bonds are broken. This was proven through an in-218 situ hybridization study (Kwon & Daniell, 2016) . In this study there was an enormous measure 219 of Bacteroidetes in the mucous layer and its substrates were predominantly 220 mucopolysaccharides. In the mucous layer, bacteria in the gut grasp and attach to a plant cell This review discussed possible methods for optimizing the delivery of Cas9 nucleases.
227
Delivering Cas-9 nucleases are negatively affected by off-target DNA sites, sgRNA design, off-228 target cleavage, Cas9 activation, and the method of delivery. This review focuses on delivery methods to effectively guide the transport of Cas9-sgRNA nucleases through the GI tract in vivo.
230
Delivery through the digestive and GI tract may provide a valuable alternative method. The GI 231 tract consist of 70% of the total immune system. The lining of the GIT contains a layer of 232 microflora bacteria, a mucosal layer, and epithelial cells, and immune cells. The Peyer's Patch is Our review attempted to present alternatives for delivering CRISPR Cas9-sgRNA 240 nucleases through the gastrointestinal tract. We reviewed the internal processes for delivery 241 through the ingestion of nanoparticles as the lipid nanoparticles. Evidence for a more successful 242 Cas9 delivery through the GIT was explained by revisiting the structure and function of the gut 
